Laboratorio Reig Jofre, S.A.

LSE:0RB1 Stock Report

Market Cap: €225.8m

Laboratorio Reig Jofre Valuation

Is 0RB1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RB1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0RB1 (€2.86) is trading below our estimate of fair value (€5.76)

Significantly Below Fair Value: 0RB1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RB1?

Key metric: As 0RB1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0RB1. This is calculated by dividing 0RB1's market cap by their current earnings.
What is 0RB1's PE Ratio?
PE Ratio23.6x
Earnings€9.55m
Market Cap€225.77m

Price to Earnings Ratio vs Peers

How does 0RB1's PE Ratio compare to its peers?

The above table shows the PE ratio for 0RB1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.5x
ANCR Animalcare Group
32.1x15.8%UK£148.5m
EAH ECO Animal Health Group
42.7x34.2%UK£44.7m
HIK Hikma Pharmaceuticals
19x12.8%UK£4.3b
BVXP Bioventix
24.2xn/aUK£195.7m
0RB1 Laboratorio Reig Jofre
23.6x25.2%€225.8m

Price-To-Earnings vs Peers: 0RB1 is good value based on its Price-To-Earnings Ratio (23.6x) compared to the peer average (29.5x).

Price to Earnings Ratio vs Industry

How does 0RB1's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0RB1 23.6xIndustry Avg. 20.3xNo. of Companies10PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0RB1 is expensive based on its Price-To-Earnings Ratio (23.6x) compared to the European Pharmaceuticals industry average (20.3x).

Price to Earnings Ratio vs Fair Ratio

What is 0RB1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RB1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0RB1's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

7D

-1.7%

1Y

-6.3%